このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

OrthoPediatrics マネジメント

マネジメント基準チェック /34

OrthoPediatrics'の CEO はDavid Baileyで、 Jun2020年に任命され、の在任期間は 2.58年です。の年間総報酬は$ 2.72Mで、 18.4%給与と81.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.96%を直接所有しており、その価値は$ 6.76M 。経営陣と取締役会の平均在任期間はそれぞれ3.7年と12.4年です。

主要情報

David Bailey

最高経営責任者

US$2.7m

報酬総額

CEO給与比率	18.4%
CEO在任期間	4yrs
CEOの所有権	1.0%
経営陣の平均在職期間	3.7yrs
取締役会の平均在任期間	12.4yrs

経営陣の近況

Recent updates

OrthoPediatrics Corp. (NASDAQ:KIDS) Just Reported And Analysts Have Been Lifting Their Price Targets

May 09

OrthoPediatrics (NASDAQ:KIDS) Has Debt But No Earnings; Should You Worry?

May 07

Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S

Apr 10

Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S

Dec 20

CEO報酬分析

OrthoPediatrics の収益と比較して、David Bailey の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$22m
Dec 31 2023	US$3m	US$500k	-US$21m
Sep 30 2023	n/a	n/a	-US$22m
Jun 30 2023	n/a	n/a	US$976k
Mar 31 2023	n/a	n/a	US$4m
Dec 31 2022	US$1m	US$415k	US$1m
Sep 30 2022	n/a	n/a	US$9m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$906k	US$371k	-US$16m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$33m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$898k	US$371k	-US$33m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$15m
Dec 31 2019	US$836k	US$300k	-US$13m
Sep 30 2019	n/a	n/a	-US$11m
Jun 30 2019	n/a	n/a	-US$10m
Mar 31 2019	n/a	n/a	-US$10m
Dec 31 2018	US$590k	US$266k	-US$12m
Sep 30 2018	n/a	n/a	-US$25m
Jun 30 2018	n/a	n/a	-US$26m
Mar 31 2018	n/a	n/a	-US$26m
Dec 31 2017	US$483k	US$258k	-US$24m

報酬と市場: Davidの総報酬 ($USD 2.72M ) は、 US市場 ($USD 3.39M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Davidの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

David Bailey (45 yo)

4yrs

在職期間

US$2,721,840

報酬

Mr. David R. Bailey serves as the Chief Executive Officer at OrthoPediatrics Corp. since June 01, 2021. He serves as the President at OrthoPediatrics Corp. since June 3, 2020 and serves as its Director sin...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Mark Throdahl	Executive Chairman	15.4yrs	データなし	0.76% $ 5.4m
David Bailey	President	4yrs	US$2.72m	0.96% $ 6.9m
Fred Hite	CFO, Principal Financial & Accounting Officer	9.3yrs	US$2.04m	0.63% $ 4.5m
Daniel Gerritzen	Executive VP of Legal	15.4yrs	US$1.35m	0.37% $ 2.6m
Gregory Odle	President of Scoliosis	no data	US$1.35m	0.48% $ 3.5m
Kevin Unger	President of Enabling Technologies	1.1yrs	US$22.50k	データなし
Joseph Hauser	President of Trauma & Deformity Correction	3.4yrs	US$1.35m	0.38% $ 2.7m
Joel Batts	Senior Vice President of Clinical & Regulatory Affairs	1.7yrs	データなし	データなし
Mark Karshner	Senior Vice President of International Sales	8.4yrs	データなし	データなし

3.7yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: KIDSの経営陣は経験豊富であると考えられます ( 3.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Mark Throdahl	Executive Chairman	15.4yrs	データなし	0.76% $ 5.4m
David Bailey	President	2.6yrs	US$2.72m	0.96% $ 6.9m
Fred Hite	CFO, Principal Financial & Accounting Officer	8.8yrs	US$2.04m	0.63% $ 4.5m
Terry Schlotterback	Lead Independent Director	15.4yrs	US$185.00k	0.087% $ 621.7k
Peter Armstrong	Chair of Surgeon Advisory Board	no data	データなし	データなし
David Pelizzon	Director	13.4yrs	US$180.00k	0.10% $ 734.9k
Bryan Hughes	Independent Director	12.4yrs	US$190.00k	0.054% $ 384.0k
Henry Chambers	Member of Surgeon Advisory Board	no data	データなし	データなし
J. Gordon	Member of Surgeon Advisory Board	no data	データなし	データなし
H. Graham	Member of Surgeon Advisory Board	no data	データなし	データなし
Daniel Hoernschemeyer	Member of Surgeon Advisory Board	no data	データなし	データなし
Marie Infante	Independent Director	10.4yrs	US$185.00k	0.048% $ 340.2k

12.4yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: KIDSの取締役会は経験豊富で経験豊富です ( 12.4年の平均在任期間)。

OrthoPediatrics マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

OrthoPediatrics Corp., Annual General Meeting, May 24, 2024

President recently sold US$89k worth of stock

Insider recently sold US$81k worth of stock

Key Executive recently sold US$190k worth of stock

OrthoPediatrics Corp. Announces Election of George Dyer to its Board of Directors

Insider recently sold US$112k worth of stock

Recent updates

New minor risk - Shareholder dilution

OrthoPediatrics Corp. (NASDAQ:KIDS) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 7.5% to US$43.00

OrthoPediatrics Corp. Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

OrthoPediatrics (NASDAQ:KIDS) Has Debt But No Earnings; Should You Worry?

OrthoPediatrics Corp. Receives Breakthrough Device” Designation from FDA for eLLi Growing Rod System for Pediatric Patients with Scoliosis

OrthoPediatrics Corp. to Report Q1, 2024 Results on May 06, 2024

Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S

OrthoPediatrics Corp., Annual General Meeting, May 24, 2024

Consensus EPS estimates fall by 29%, revenue upgraded

President recently sold US$89k worth of stock

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Orthopediatrics Corp. Reiterates Revenue Guidance for Full Year 2024

Orthopediatrics Corp. Provides Revenue Guidance for Full Year 2024

OrthoPediatrics Corp. Launches New RESPONSE Rib and Pelvic Fixation System for EOS Scoliosis

Insider recently sold US$81k worth of stock

OrthoPediatrics Corp. to Report Q4, 2023 Results on Mar 06, 2024

OrthoPediatrics Corp. Provides Preliminary Unaudited Revenue Guidance Fourth Quarter and Full Year 2023 and for the Year 2024

Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S

OrthoPediatrics Corp. Reiterates Earnings Guidance for the Full Year of 2023

New minor risk - Profitability

Price target decreased by 16% to US$44.67

New minor risk - Shareholder dilution

OrthoPediatrics Corp. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 8.3% to US$50.00

OrthoPediatrics Corp. Launches DF2 Brace

OrthoPediatrics Corp. Reiterates Earnings Guidance for the Full Year of 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

OrthoPediatrics Corp. Announces the Launch and First Case Using the GIRO Growth Modulation System

Key Executive recently sold US$190k worth of stock

OrthoPediatrics Corp. Announces Election of George Dyer to its Board of Directors

OrthoPediatrics Corp. Announces Launch of Response Power Scoliosis System

Getting In Cheap On OrthoPediatrics Corp. (NASDAQ:KIDS) Might Be Difficult

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 21%

Insider recently sold US$112k worth of stock

Insider notifies of intention to sell stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

OrthoPediatrics Corp. to Report Q4, 2022 Results on Feb 28, 2023

OrthoPediatrics Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 and Fiscal Year 2023

Less than half of directors are independent

OrthoPediatrics' (NASDAQ:KIDS) Earnings Aren't As Good As They Appear

Consensus forecasts updated

Price target decreased to US$57.33

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

OrthoPediatrics Corp. Updates Revenue Guidance for the Year 2022

Less than half of directors are independent

Orthopediatrics Corp. Announces Retirement of Stephen F. Burns from Board of Directors

OrthoPediatrics Corp. to Report Q3, 2022 Results on Oct 31, 2022

OrthoPediatrics Corp. has completed a Follow-on Equity Offering in the amount of $125.124619 million.

Consensus estimates of losses per share improve by 13%

OrthoPediatrics announces public offering of stock, pre-funded warrants

Is OrthoPediatrics (NASDAQ:KIDS) Using Debt In A Risky Way?

Price target increased to US$63.00

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

OrthoPediatrics Corp. Revises Revenue Guidance for the Year 2022

OrthoPediatrics Corp. to Report Q2, 2022 Results on Aug 03, 2022

OrthoPediatrics enters distribution agreement with 3D-Side

OrthoPediatrics Corp. (NasdaqGM:KIDS) and OrthoPediatrics Canada ULC completed the acquisition of Pega Medical Inc. for CAD 33 million.

OrthoPediatrics Corp. announced that it has received $50 million in funding from Squadron Capital, LLC

Consensus forecasts updated

No longer forecast to breakeven

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Orthopediatrics Corp. Provides Revenue Guidance for the Full Year 2022

Price target decreased to US$71.67

OrthoPediatrics Corp. to Report Q1, 2022 Results on May 04, 2022

OrthoPediatrics Corp. (NasdaqGM:KIDS) acquired MD Orthopaedics, Inc. from John Mitchell for $19.6 million.

マネジメント基準チェック /34